-
Competing-risks model in screening for pre-eclampsia in twin pregnancy according to maternal factors and biomarkers at 11-13 weeks' gestation.
Francisco C, Wright D, Benkő Z, Syngelaki A, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:589-595. pdf -
ASPRE trial: performance of screening for preterm pre-eclampsia.
Rolnik DL, Wright D, Poon LCY, Syngelaki A, O'Gorman N, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:492-495. pdf -
Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia.
Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH.
N Engl J Med 2017;377:613-622. pdf -
Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia.
Wright D, Poon LC, Rolnik DL, Syngelaki A, Delgado JL, Vojtassakova D, de Alvarado M, Kapeti E, Rehal A, Pazos A, Carbone IF, Dutemeyer V, Plasencia W, Papantoniou N, Nicolaides KH.
Am J Obstet Gynecol 2017;217:685.e1-685.e5. pdf -
Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history.
Poon LC, Wright D, Rolnik DL, Syngelaki A, Delgado JL, Tsokaki T, Leipold G, Akolekar R, Shearing S, De Stefani L, Jani JC, Plasencia W, Evangelinakis N, Gonzalez-Vanegas O, Persico N, Nicolaides KH.
Am J Obstet Gynecol 2017;217:585.e1-585.e5. pdf -
Impaired placentation in women with chronic hypertension that develop preeclampsia.
Panaitescu AM, Akolekar R, Kametas N, Syngelaki A, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:496-500. pdf -
Chronic hypertension and adverse pregnancy outcomes: a cohort study.
Panaitescu AM, Syngelaki A, Prodan N, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:228-235. pdf -
A study protocol for the prospective validation study: Screening programme for pre-eclampsia (SPREE)
Tan MY, Koutoulas L, Wright D, Nicolaides KH, Poon LC.
Ultrasound Obstet Gynecol 2017;50:175-179. pdf -
Multicenter screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison to NICE guidelines and ACOG recommendations.
O' Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, de Alvarado M, Carbone IF, Dutemeyer V, Fiolna M, Frick A, Karagiotis N, Mastrodima S, de Paco Matallana C, Papaioannou G, Pazos A, Plasencia W, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:756-760. pdf -
Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation.
O'Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, Wright A, Akolekar R, Cicero S, Janga D, Jani J, Molina FS, de Paco Matallana C, Papantoniou N, Persico N, Plasencia W, Singh M, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:751-755. pdf -
Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE)
O'Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC.
BMJ Open 2016;6:e011801. pdf -
Contingent screening for preterm pre-eclampsia.
Wright D, Gallo DM, Gil Pugliese S, Casanova C, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:554-9. pdf -
Inverted Pyramid of Care.
Sonek JD, Kagan KO, Nicolaides KH.
Clin Lab Med 2016;36:305-17. pdf -
First trimester prediction of HELLP syndrome.
Oliveira N, Poon LC, Nicolaides KH, Baschat AA.
Prenat Diagn 2016;36:29-33. pdf -
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation.
O'Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH.
Am J Obstet Gynecol 2016;214:103.e1-103.e12 . pdf -
Maternal Serum Placental Growth Factor (PlGF) Isoforms 1 and 2 at 11-13 Weeks' Gestation in Normal and Pathological Pregnancies.
Nucci M, Poon LC, Demirdjian G, Darbouret B, Nicolaides KH.
Fetal Diagn Ther 2014;36:106-16.. pdf -
First-trimester maternal factors and biomarker screening for preeclampsia.
Poon LC, Nicolaides KH.
Prenat Diagn 2014;34:618-27. pdf -
Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation.
Bujold E, Roberge S, Nicolaides KH.
Prenat Diagn 2014;34:642-8. pdf -
Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks' gestation: relation to fetal and maternal characteristics and pregnancy outcomes.
Poon LC, Musci T, Song K, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2013;33:215-23. pdf -
Maternal racial origin and adverse pregnancy outcome: a cohort study.
Khalil A, Rezende J, Akolekar R, Syngelaki A, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;41:278-85.